The MUC1-C oncoprotein as a target in hematologic malignancies

Cancer Biology and Therapy

Volumn 10, Issue 5, 2010, Pages 492-494

  Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bcr Abl; CML; Differentiation; MUC1; Myeloid blasts; Peptide drugs; Self renewal; Targeted therapies

Indexed keywords

HETERODIMER; MUCIN 1;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MEMBRANE; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HEMATOLOGIC MALIGNANCY; NOTE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

CELL DIFFERENTIATION; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; MUCIN-1; MYELOPOIESIS; PROGNOSIS; PROTEIN MULTIMERIZATION;

EID: 77957116889     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.5.13150     Document Type: Note

References (12)

1. Kufe D, Inghirami G, Abe M, Hayes D, Justi- Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human versus benign breast tumors. Hybridoma 1984; 3:223-32.
2. Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874-85.
3. Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, et al. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther 2010; (In press).
4. Vermeer P, Einwalter L, Moniger T, Rokhlina T, Kern J, Zabner J, Welsh M. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003; 422:322-6. (Pubitemid 36378360)
5. Arlen P, Gulley J, Madan R, Hodge J, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007; 27:451-62.
6. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3β-mediated phosphorylation and degradation of β-catenin. Cancer Res 2005; 65:10413-22.
7. Kufe D. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009; 8:1199-203.
8. Leng Y, Cao C, Ren J, Huang L, Chen D, Kufe D. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282:19321-30.
9. Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast cancer cells. Cancer Res 2009; 69:7013-21.
10. Bitler B, Menzl I, Huerta C, Sands B, Knowlton W, Chang A, Schroeder J. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009; 15:100-9.
11. Kawano T, Ito M, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res 2007; 67:11576-84.
12. Druker B. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112:4808-17.